Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
October 31, 2023
FDA-compliant manufacture of intravenous Ketamine is a required component of a New Drug Application Intravenous Ketamine has become widely used for treating depression and suicidality but has...
-
October 26, 2023
"Study May Proceed" letter received from FDA IND preclinical requirements are consistent with studies already in progress to support treatment of Bipolar Depression Potential to initiate...
-
October 12, 2023
Previously announced data sharing agreement for intravenous ketamine Newly available data highlight the need for a labeled form of IV ketamine that can qualify for insurance reimbursement Need for...
-
October 5, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chief Scientist of NRx...
-
October 2, 2023
Allows initiation of the NRX-101 commercial development to treat Chronic Pain Company plans to seek Fast Track and Breakthrough Therapy Designations from FDA while awaiting near-term results of...
Click here to view our corporate presentation or on the image below